Company profile: Gilead
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for critical diseases, discovering, developing, manufacturing and commercializing treatments across virology, oncology and inflammation. Portfolio includes Biktarvy and Descovy for HIV-1 (treatment and PrEP) and Epclusa for HCV, with efforts to transform viral diseases into manageable conditions and expand access to care.
Products and services
- Biktarvy: A clinical-grade complete regimen that treats HIV-1 in adults and pediatric patients weighing at least 14 kg, for treatment-naïve or virologically suppressed individuals on a stable regimen
- Descovy: An antiretroviral component used with other agents to treat HIV-1 and as PrEP to reduce HIV-1 risk in at-risk adults and adolescents
- Epclusa: An oral therapy indicated for chronic HCV in patients 3 years and older, with or without cirrhosis, and with ribavirin for decompensated cirrhosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Gilead
Alvotech
HQ: Iceland
Website
- Description: Provider of fully integrated biosimilar development and manufacturing, including monoclonal antibodies for immunology, oncology, and ophthalmology. Offers R&D and clinical services and worldwide commercial partnerships to expand access to biologic medicines. Employs single-use technology and Iceland’s renewable energy. Portfolio includes AVT02 (adalimumab) and AVT04 (ustekinumab), approved across multiple regions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alvotech company profile →
Paladin Labs
HQ: Canada
Website
- Description: Provider of innovative pharmaceutical products, headquartered in Montreal, Canada, specializing in researching, developing, acquiring, and in-licensing for the Canadian and world markets, supported by a focused national sales team and proven marketing expertise.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paladin Labs company profile →
Schwarz Pharma
HQ: Germany
Website
- Description: Provider of pharmaceutical product development, bringing approved and late-stage new compounds with complementary therapeutic and geographic focus, supported by strong talent and cultural fit.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Schwarz Pharma company profile →
KAI Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel therapeutics through drug discovery and development, with multiple clinical-stage programs in cardiovascular disease, kidney disease, and pain; lead candidate KAI-9803 is in Phase 2b (PROTECTION AMI) evaluating reduction of myocardial injury in heart attack.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KAI Pharmaceuticals company profile →
Vicore Pharma
HQ: Sweden
Website
- Description: Provider of pharmaceuticals for severe lung disorders, developing drugs acting through the angiotensin II type 2 (AT2) receptor, including buloxibutid (C21), an orally available ATRAG in phase 2a for idiopathic pulmonary fibrosis (IPF) with orphan drug designation in the EU, and Almee, a digital therapeutic based on cognitive behavioral therapy to address the psychological impact of pulmonary fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicore Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Gilead
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Gilead
2.2 - Growth funds investing in similar companies to Gilead
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Gilead
4.2 - Public trading comparable groups for Gilead
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →